Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Kita-ku, Okayama, Japan.
National Center Hospital, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo, Japan.
J Alzheimers Dis. 2022;86(1):111-123. doi: 10.3233/JAD-215318.
Recent studies have revealed that atrial fibrillation (AF) patients have a high risk of developing cognitive impairment, vascular dementia, and Alzheimer's disease (AD). Some reports suggest that the application of oral anticoagulant with an appropriate dose may have a preventive effect on AD. However, which oral anticoagulant drug is more appropriate for preventing AD and the underlying mechanism(s) is still unknown.
The aim of the present study was to assess the treatment effect of rivaroxaban administration as well as investigate the roles of PAR-1 and PAR-2 in the AD + CAA mice model.
In the present study, we compared a traditional oral anticoagulant, warfarin, and a direct oral anticoagulant (DOAC), rivaroxaban, via long-term administration to an AD with cerebral amyloid angiopathy (CAA) mice model.
Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-β deposition through PAR-1/PAR-2 inhibition in the AD + CAA mice model compared with warfarin and no-treatment groups.
The present study demonstrates that rivaroxaban can attenuate AD progress and can be a potential choice to prevent AD.
最近的研究表明，心房颤动（AF）患者发生认知障碍、血管性痴呆和阿尔茨海默病（AD）的风险较高。一些报告表明，应用适当剂量的口服抗凝剂可能对 AD 具有预防作用。然而，哪种口服抗凝药物更适合预防 AD 以及其潜在机制尚不清楚。
本研究旨在评估利伐沙班给药的治疗效果，并研究 PAR-1 和 PAR-2 在 AD+CAA 小鼠模型中的作用。
本研究通过长期给予 AD 合并脑淀粉样血管病（CAA）小鼠模型一种传统口服抗凝剂华法林和一种直接口服抗凝剂（DOAC）利伐沙班，对其进行比较。
与华法林和未治疗组相比，利伐沙班通过抑制 PAR-1/PAR-2，减轻了 AD+CAA 小鼠模型中的神经炎症、血脑屏障功能障碍、记忆缺陷和淀粉样β沉积。
本研究表明，利伐沙班可以减轻 AD 的进展，可能是预防 AD 的一种选择。
Zotero 插件